Abstract
Objective: The results of a cytological diagnosis and high-risk (hr)HPV test in cervical cancer screening in our hospital from 2021 to 2023 are summarized and reviewed.
Methods: Liquid-based cytology specimens were diagnosed according to The Bethesda System. The hrHPV test was performed by Aptima HPV.
Results: The total number of cervical cancer screens performed was 18,220. The actual number of examinees was 10,129, with an age range from 18 to 90 years. Two specimens were not analyzed because of the small number of cells included. Among 18,218 specimens, 894 (4.9%) were diagnosed with ASC-US or higher. The actual number of hrHPV tests was 209, and hrHPV was positive in 19 (9.1%). The rates of the diagnosis of ASC-US or higher in hrHPV-negative and hrHPV-positive examinees were 6.3 and 57.9%, respectively. HSIL was noted in 5 out of 9 examinees <40 years and in 2 out of 10 examinees ≥40 years. In three hrHPV-positive examinees, the cytological diagnosis changed from NILM to LSIL or HSIL in three years.
Conclusion: Based on the present results, a cytological diagnosis is recommended for young examinees. hrHPV-positive examinees need to be carefully followed up.
